Novartis combo therapy for melanoma gets FDA priority review

ZURICH (Reuters) - The U.S. Food and Drug Administration has granted priority review for Novartis's Tafinlar in combination with Mekinist for treating some patients with advanced melanoma, the Swiss drugmaker said on Friday.